~~<i id='1F6F8C5F4C'><strike id='1F6F8C5F4C'><tt id='1F6F8C5F4C'><pre id='1F6F8C5F4C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：Wikipedia 2025-08-12 08:29:42 - browse：26

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： A virus, fished out of a lake, may have saved a man’s life

entertainment

explore

hotspot

knowledge

explore

hotspot

AdobeAsafetusdevelops,itsbodyisbathedinamnioticfluid:awarm,saltysoupofnutrients,hormones,andantibodi

WSS

Harvard's David Sinclair gets blowback over aging

Physician executives need more than on

Histogen: Failed biotech offers rare public look inside

Streamlined flu vaccines recommended by FDA advisory panel

FDA rejects Alnylam's heart disease treatment over insufficient data

Change Healthcare: What is it, why does its cyberattack matter?

focus

focus

entertainment

Walensky prepares to leave CDC — and Congress — behind

Was Amgen transparent enough on FDA's concern on cancer drug?

Heart attack and stroke risk calculators need revising

Liquid biopsy for lung cancer is launched by Delfi

Jerome Adams on the need for new antivirals for Covid

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Medical records are filled with copy

Medicare drug price negotiation hearing pits pharma v Biden admin

The high cost of giving birth even with insurance

The public health thinking behind the CDC’s new Covid guidance

explore

The future of health care in the House

Harvard's David Sinclair gets blowback over aging

First over

Stem cell biologist probes earliest stages of human development

AI can decode, harness the power of the humane immune system

The public health thinking behind the CDC’s new Covid guidance

hotspot

knowledge

explore

hotspot